The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model

Introduction Vaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites. Methods Utilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival. Results Mice vaccinated with AdCOVID via the intramuscular or intranasal route and subsequently challenged with SARS-CoV-2 showed that animals vaccinated intranasally had improved cellular and mucosal antibody responses. Additionally, intranasally vaccinated animals had significantly better viremic control, and protection from lethal infection compared to intramuscularly vaccinated animals. Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to naïve co-housed mice compared to intramuscular vaccination. Discussion Our data provide convincing evidence for the use of intranasal vaccination in protecting against SARS-CoV-2 infection and transmission.

[1]  M. Esteban,et al.  Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection , 2022, Frontiers in Immunology.

[2]  Y. Kreiss,et al.  Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection , 2022, JAMA network open.

[3]  Kenneth A. Matreyek,et al.  Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2 , 2022, Viruses.

[4]  Choong Man Lee,et al.  Resident Memory B Cells in Barrier Tissues , 2022, Frontiers in immunology.

[5]  Lindsay N. Carpp,et al.  Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial , 2022, Nature Communications.

[6]  S. Jonjić,et al.  ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination , 2022, European journal of immunology.

[7]  William F. Fadel,et al.  Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[8]  J. Casado,et al.  Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity , 2022, Frontiers in Microbiology.

[9]  D. Barouch,et al.  Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron , 2022, Nature.

[10]  S. Schrag,et al.  Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.

[11]  Jordan J. Clark,et al.  Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.

[12]  R. Kishony,et al.  Waning of SARS-CoV-2 booster viral-load reduction effectiveness , 2021, Nature Communications.

[13]  M. Diamond,et al.  mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2 , 2021, bioRxiv.

[14]  T. Ndung’u,et al.  Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.

[15]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[16]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[17]  A. Telenti,et al.  Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift , 2021, Nature.

[18]  A. Iwasaki,et al.  Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA , 2021, Science Immunology.

[19]  K. To,et al.  Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant , 2021, Vaccines.

[20]  Scott M Elliott,et al.  Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.

[21]  S. Kissler,et al.  Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons , 2021, The New England journal of medicine.

[22]  K. Überla,et al.  Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization , 2021, Nature Communications.

[23]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[24]  M. Klompas.  Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination. , 2021, JAMA.

[25]  D. Stuart,et al.  The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants , 2021, Cell Host & Microbe.

[26]  Chaim A. Schramm,et al.  Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates , 2021, Science.

[27]  Manish M Patel,et al.  Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[28]  J. Vekemans,et al.  Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial , 2021, International Journal of Infectious Diseases.

[29]  A. Wilder-Smith.  What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant? , 2021, The Lancet Infectious Diseases.

[30]  M. Davenport,et al.  Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain , 2021, Cell Reports.

[31]  Hyeong Mi Kim,et al.  Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study , 2021, Science.

[32]  E. Goldman.  How the unvaccinated threaten the vaccinated for COVID-19: A Darwinian perspective , 2021, Proceedings of the National Academy of Sciences.

[33]  S. Bhatt,et al.  SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion , 2021, Nature.

[34]  Judith Tsamir,et al.  Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study , 2021, Clinical Microbiology and Infection.

[35]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[36]  C. Qin,et al.  Expression pattern and function of SARS-CoV-2 receptor ACE2 , 2021, Biosafety and Health.

[37]  S. Qiu,et al.  Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge , 2021, Vaccines.

[38]  J. Mascola,et al.  Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates , 2021, Science.

[39]  S. Anzick,et al.  Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models , 2021, Science Translational Medicine.

[40]  B. Haynes,et al.  Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates , 2021, Science Translational Medicine.

[41]  X. Xia.  Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines , 2021, Vaccines.

[42]  A. Venkatakrishnan,et al.  Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines , 2021, Med.

[43]  D. Meyerholz,et al.  Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5–based COVID-19 vaccine , 2021, Science Advances.

[44]  M. Diamond,et al.  SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses , 2021, Nature.

[45]  M. Drebot,et al.  SARS-CoV-2 infection and transmission in the North American deer mouse , 2021, Nature Communications.

[46]  J. Bloom,et al.  Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection , 2021, Science Translational Medicine.

[47]  H. van Bakel,et al.  SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 , 2021, Cell.

[48]  J. Bloom,et al.  The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD , 2021, bioRxiv.

[49]  L. Martínez-Sobrido,et al.  Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern , 2021, bioRxiv.

[50]  Frederic A. Fellouse,et al.  Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2 , 2021, Communications Biology.

[51]  Ahmed Abdul Azim,et al.  Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. , 2021, JAMA.

[52]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[53]  Z. Chagla.  The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose , 2021, Annals of Internal Medicine.

[54]  A. Fauci,et al.  SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn , 2021, Annals of Internal Medicine.

[55]  J. Costoya,et al.  SARS-CoV-2 infection in K18-ACE2 transgenic mice replicates human pulmonary disease in COVID-19 , 2021, Cellular & Molecular Immunology.

[56]  S. Farhadian,et al.  Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2021, The Journal of experimental medicine.

[57]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[58]  Justin M. Richner,et al.  mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. , 2020, PLoS pathogens.

[59]  J. Harty,et al.  Influenza-Specific Lung-Resident Memory CD8+ T Cells. , 2020, Cold Spring Harbor perspectives in biology.

[60]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[61]  C. Akdis,et al.  Risk factors for severe and critically ill COVID‐19 patients: A review , 2020, Allergy.

[62]  V. Thiel,et al.  Coronavirus biology and replication: implications for SARS-CoV-2 , 2020, Nature Reviews Microbiology.

[63]  L. Holtzer,et al.  Measurement of Cellular Immune Response to Viral Infection and Vaccination , 2020, Frontiers in Immunology.

[64]  Penghua Wang,et al.  Mechanisms of SARS-CoV-2 Transmission and Pathogenesis , 2020, Trends in Immunology.

[65]  I. Wilson,et al.  Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies , 2020, Biochemical and Biophysical Research Communications.

[66]  Shibo Jiang,et al.  Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2 , 2020, Signal Transduction and Targeted Therapy.

[67]  M. Marschollek,et al.  Risk factors for Covid-19 severity and fatality: a structured literature review , 2020, Infection.

[68]  R. DiPaolo,et al.  Characterization of cells susceptible to SARS-COV-2 and methods for detection of neutralizing antibody by focus forming assay , 2020, bioRxiv.

[69]  Lisa E. Gralinski,et al.  A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 , 2020, Cell.

[70]  M. Endres,et al.  A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model , 2020, bioRxiv.

[71]  A. Munasinghe,et al.  SARS-CoV-2 and the pandemic of COVID-19 , 2020, Postgraduate Medical Journal.

[72]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[73]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[74]  Rebecca J. Loomis,et al.  Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.

[75]  A. d’Arminio Monforte,et al.  ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population , 2020, European Journal of Human Genetics.

[76]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[77]  M. Zervos,et al.  Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit , 2020, JAMA network open.

[78]  Leora I. Horwitz,et al.  Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study , 2020, BMJ.

[79]  H. Yen,et al.  Peer Review File Manuscript Title: Pathogenesis and transmission of SARS-CoV-2 in golden Syrian hamsters , 2020 .

[80]  Jean-Marc Rolain,et al.  ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome , 2020, Journal of Microbiology, Immunology and Infection.

[81]  Huan Li,et al.  Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  Proton Rahman,et al.  Genetic variability of human angiotensin‐converting enzyme 2 (hACE2) among various ethnic populations , 2020, bioRxiv.

[83]  D. Mathieu,et al.  High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation , 2020, Obesity.

[84]  Eun-Ha Kim,et al.  Infection and Rapid Transmission of SARS-CoV-2 in Ferrets , 2020, Cell Host & Microbe.

[85]  S. Rubino,et al.  The novel zoonotic COVID-19 pandemic: An expected global health concern. , 2020, Journal of infection in developing countries.

[86]  Jun Zheng.  SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat , 2020, International journal of biological sciences.

[87]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[88]  T. Randall,et al.  Resident Memory B Cells. , 2020, Viral immunology.

[89]  Xin-Zi Tang,et al.  A case of mistaken identity: The MAR-1 antibody to mouse FcεRIα cross-reacts with FcγRI and FcγRIV. , 2019, The Journal of allergy and clinical immunology.

[90]  T. Randall,et al.  The establishment of resident memory B cells in the lung requires local antigen encounter , 2018, Nature Immunology.

[91]  J. Harty,et al.  Repeated Antigen Exposure Extends the Durability of Influenza-Specific Lung-Resident Memory CD8+ T Cells and Heterosubtypic Immunity. , 2018, Cell reports.

[92]  J. Harty,et al.  Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity , 2017, Science Immunology.

[93]  M. Diamond,et al.  Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants , 2011, The Journal of experimental medicine.

[94]  M. Diamond,et al.  A Temporal Role Of Type I Interferon Signaling in CD8+ T Cell Maturation during Acute West Nile Virus Infection , 2011, PLoS pathogens.

[95]  R. Schreiber,et al.  Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.